Therapy

Thymopentin Delayed HIV Progression in Stanford Study

Published in AIDS Weekly, August 14th, 1995

Thymopentin delayed HIV progression in the presence of a key zidovudine resistance mutation, high viral load and low CD4 count in a study involving 352 asymptomatic HIV infected persons.

Additional data from the study, first reported in the March 1995 Journal of AIDS, were presented at the International Symposium on Clinical Immunology, held July 20-23, 1995 in San Francisco, California.

The 48 week placebo controlled double-blind study, conducted by T.C. Merigan and colleagues at California's Stanford University, demonstrated that thymopentin (TP5) delayed disease progression to AIDS. Additional analyses assessed which subjects at study entry are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-08-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry